Research map: Impact of updated NCCN guidelines on clinical management and risk communication for CHEK2 p.I157T carriers in breast cancer

Back to the article

Papers in this map

  1. Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations · Hanne E.J. Meijers-Heijboer · 2002 · 1113 citations · Cited by this paper
  2. Colonoscopy findings and polyp pathology in CHEK2 carriers: a single center experience · 2026 · Related
  3. A Population-Based Study of Genes Previously Implicated in Breast Cancer · Chunling Hu · 2021 · 899 citations · Cited by this paper
  4. Familial risks in prostate cancer between brothers and half-brothers as clues to germline genetic and environmental causes · 2026 · Related
  5. Financial Hardships Experienced by Cancer Survivors: A Systematic Review · Cheryl Altice · 2016 · 871 citations · Cited by this paper
  6. Attenuated Li–Fraumeni syndrome with TP53 p.R181H in a Japanese patient with metastatic rectal adenocarcinoma: a case report · 2026 · Related
  7. CHEK2 Is a Multiorgan Cancer Susceptibility Gene · Cezary Cybulski · 2004 · 560 citations · Cited by this paper
  8. Patient-derived outcome assessment of knowledge, communication, and management in those diagnosed with BAP1-tumor predisposition syndrome · 2026 · Related
  9. Cancer overdiagnosis: a biological challenge and clinical dilemma · Sudhir Srivastava · 2019 · 345 citations · Cited by this paper
  10. Breast cancer phenotypes in carriers of pathogenic POT1 variants · 2026 · Related
  11. Impact of provider-patient communication on cancer screening adherence: A systematic review · Emily Peterson · 2016 · 312 citations · Cited by this paper
  12. Homozygous TP53 alterations: a case of a biallelic splice variant and a brief review of the literature · 2026 · Related
  13. Policy Support For Patient-Centered Care: The Need For Measurable Improvements In Decision Quality · Karen Sepucha · 2004 · 302 citations · Cited by this paper
  14. Genotypic and phenotypic characteristics of germline TP53 variant carriers: experience from two cancer genetic counseling units · 2026 · Related
  15. Patient re-contact after revision of genomic test results: points to consider—a statement of the American College of Medical Genetics and Genomics (ACMG) · Karen L. David · 2018 · 141 citations · Cited by this paper
  16. When screentime fails: initiative to improve completion of hereditary cancer genetic testing after telemedicine counseling · 2026 · Related
  17. Management of individuals with germline pathogenic/likely pathogenic variants in CHEK2: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG) · HELEN LOUISE HANSON · 2023 · 90 citations · Cited by this paper
  18. Trends in breast reconstruction for BRCA1/2, PALB2 and other high penetrance germline pathogenic variant carriers undergoing risk reducing mastectomy · 2026 · Related
  19. Factors Influencing Cancer Risk Perception in High Risk Populations: A Systematic Review · Jon Charles Tilburt · 2011 · 82 citations · Cited by this paper
  20. Biallelic germline MBD4 mutations predispose to colorectal polyposis, hypermutated AML, and schwannomas · 2026 · Related
  21. What is lacking in current decision aids on cancer screening? · Masahito Jimbo · 2013 · 65 citations · Cited by this paper
  22. Patient survival and tumor characteristics associated with CHEK2:p.I157T – findings from the Breast Cancer Association Consortium · Taru Muranen · 2016 · 54 citations · Cited by this paper
  23. Differences in cancer prevalence among CHEK2 carriers identified via multi-gene panel testing · Erin G. Sutcliffe · 2020 · 39 citations · Cited by this paper
  24. Screening for cancer: the economic, medical, and psychosocial issues · Joel V. Brill · 2020 · 35 citations · Cited by this paper
  25. Clinical usefulness of NGS multi-gene panel testing in hereditary cancer analysis · Federico Anaclerio · 2023 · 33 citations · Cited by this paper
  26. Breast and colorectal cancer risks among over 6,000 CHEK2 pathogenic variant carriers: A comparison of missense versus truncating variants · Erin Mundt · 2023 · 26 citations · Cited by this paper
  27. Engaging Patients in Decisions About Cancer Screening: Exploring the Decision Journey Through the Use of a Patient Portal · Steven H. Woolf · 2017 · 25 citations · Cited by this paper
  28. Cancer Prevention in Primary Care: Perception of Importance, Recognition of Risk Factors and Prescribing Behaviors · Goli Samimi · 2019 · 18 citations · Cited by this paper
  29. Risk perception and disease knowledge in attendees of a community-based lung cancer screening programme · Mikey B Lebrett · 2022 · 16 citations · Cited by this paper
  30. “I wish that there was more info”: characterizing the uncertainty experienced by carriers of pathogenic ATM and/or CHEK2 variants · Kathryn G. Reyes · 2021 · 13 citations · Cited by this paper
  31. Factors Associated With the Overuse of Colorectal Cancer Screening: A Systematic Review · Zachary Predmore · 2018 · 12 citations · Cited by this paper
  32. Practices and Views of US Oncologists and Genetic Counselors Regarding Patient Recontact After Variant Reclassification: Results of a Nationwide Survey · Sukh Makhnoon · 2023 · 12 citations · Cited by this paper
  33. Longitudinal adherence to breast cancer surveillance following cancer genetic testing in an integrated health care system · Sarah A. Knerr · 2023 · 8 citations · Cited by this paper
  34. Evaluating the role of CHEK2 p.(Asp438Tyr) allele in inherited breast cancer predisposition · Timo A. Kumpula · 2023 · 7 citations · Cited by this paper
  35. When variants are reclassified—the importance of personalized communication · Madison K. Kilbride · 2020 · 6 citations · Cited by this paper
  36. Letter to the Editor: CHEK2 I157T - Pluto Among Numerous Low-Risk Genetic Factors Requiring Discharge From a Range of Pathogenic Variants? · Maxim V. Ivanov · 2022 · 6 citations · Cited by this paper
  37. CHEK2-related breast cancer: real-world challenges · Luiza Nardin Weis · 2025 · 5 citations · Cited by this paper
  38. Comparing Cancer Risk Management between Females with Truncating CHEK2 1100delC versus Missense CHEK2 I157T Variants · Diego Garmendia · 2024 · 3 citations · Cited by this paper
  39. A Comprehensive Cancer Risk Management Clinic for Families With Hereditary Cancer Syndromes: Outcomes After 6 Years · Kara Rogen · 2023 · 2 citations · Cited by this paper

Source: OpenAlex (CC0)